Ten Rules for Conducting Retrospective Pharmacoepidemiological Analyses: Example COVID-19 Study.

Area of Science:

• Pharmacoepidemiology
• Health Data Analysis
• Causal Inference

Background:

• Evaluating pharmaceutical treatments requires robust evidence, often necessitating randomized controlled trials (RCTs).
• Observational studies can provide preliminary evidence but face challenges due to non-randomized exposure and data collection limitations.
• The COVID-19 pandemic highlighted the need for efficient evaluation of treatment hypotheses.

Purpose of the Study:

• To introduce a framework of 10 rules for conducting retrospective pharmacoepidemiological analyses of observational health care data.
• To guide researchers in assessing treatment hypotheses and informing the design of subsequent randomized controlled trials.
• To provide a practical approach for leveraging observational data in drug development and evaluation, especially during public health crises.

Main Methods:

• Development of a 10-rule framework for end-to-end retrospective pharmacoepidemiological analysis.
• Utilizing a hypothetical COVID-19 treatment study as a running example.
• Integration of expertise from epidemiology, causal analysis, medical specialties, and data sources.

Main Results:

• The proposed 10 rules provide a structured approach to analyzing observational health care data.
• A detailed supplement offers a practical guide for implementing each rule.
• Properly executed analyses can effectively inform decisions regarding the initiation and design of randomized controlled trials.

Conclusions:

• Retrospective pharmacoepidemiological analysis, guided by these rules, is crucial for evidence-based treatment evaluation.
• This framework enhances the efficiency and credibility of investigating pharmaceutical treatments.
• The methodology has significant implications for future pandemic preparedness and response strategies.